GSK (GSK) Stock Drops 3% Despite Q1 Beat: Legal Provisions Cloud the Picture

Key Takeaways

• GSK delivered Q1 core earnings of 46.5p per share, surpassing the 43.5p consensus forecast
• Approximately 50% of the profit outperformance stemmed from legal settlement adjustments rather than operational strength
• Shingrix vaccine revenue surged 20% to £1.0 billion, while RSV vaccine Arexvy declined 18%
• Full-year financial targets remain intact, though currency headwinds from stronger Sterling are intensifying
• Shares dropped approximately 3% following the earnings announcement

GSK delivered first-quarter financial results that exceeded Wall Street projections on Wednesday, yet the pharmaceutical giant’s shares tumbled as the market scrutinized the underlying drivers. The stock retreated roughly 3% following the release.

Core operating profit for the quarter ending March 31 climbed 10% on a constant currency basis to £2.65 billion, significantly outpacing the company-compiled analyst consensus of £2.46 billion. Core earnings per share reached 46.5 pence, representing a 9% year-over-year increase and beating the 43.5 pence projection.

GSK plc, GSK

However, equity research firm Jefferies promptly highlighted that approximately half of the earnings surprise originated from legal settlement provision adjustments rather than fundamental business momentum. “Core Operating Income and Core EPS both 7% ahead of consensus, but c50% of that driven by legal settlement provisions,” analysts at the firm noted.

Revenue increased 5% at constant currency to £7.6 billion, aligning with analyst expectations. While respectable, the top-line performance alone wasn’t enough to excite investors.

Revenue Performance by Division

The Specialty Medicines segment delivered the strongest performance, advancing 14% to £3.2 billion. HIV franchise sales reached £1.8 billion, marking a 10% gain. The respiratory, immunology, and oncology portfolio expanded 28% to £0.5 billion, albeit from a more modest revenue base.

Vaccine sales totaled £2.1 billion, representing a 4% increase. Shingrix, the company’s blockbuster shingles prevention vaccine, stood out with revenue soaring 20% to £1.0 billion—a quarterly record. Meanwhile, Arexvy, the RSV vaccine, posted £0.1 billion in sales, down 18%, which GSK attributed to normal seasonal fluctuations.

General Medicines proved to be the underperformer, contracting 6% to £2.3 billion and falling short of analyst projections by 3%.

Financial Outlook and Currency Challenges

GSK maintained its 2026 financial guidance, continuing to project revenue growth between 3% and 5% alongside core operating profit expansion of 7% to 9%.

Nevertheless, Sterling’s appreciation versus the U.S. dollar is creating pressure on reported figures. Jefferies observed that the foreign exchange headwind is pushing consensus forecasts toward the upper boundary of management’s guided ranges.

GSK also revealed adjustments to its investor relations schedule. Chief Executive Emma Walmsley and newly appointed commercial leader Luke Miels will present a comprehensive strategy briefing alongside second-quarter earnings, replacing a previously scheduled HIV-focused investor event.

The pharmaceutical company declared a quarterly dividend of 15 pence per share.

Over the trailing twelve months, GSK stock has appreciated 42%, substantially outperforming both the FTSE 100 index and the wider Stoxx 600 benchmark.